Cardiovascular disease and modifiable cardiometabolic risk factors

Clinical Cornerstone

Volumn 8, Issue 3, 2007, Pages 11-28

  Cannon, Christopher P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; GLUCAGON LIKE PEPTIDE 1; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METOPROLOL SUCCINATE; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; RAMIPRIL; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; UNITED STATES;

EID: 42649084025     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(07)80025-1     Document Type: Article

References (73)

1. Rosamond W., Flegal K., Friday G., et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Spinler S. Challenges associated with metabolic syndrome. Pharmacotherapy 26 (2006) 209S-217S
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
4. Olshansky S., Passaro D., Hershow R., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352 (2005) 1138-1145
5. Razak F., Anand S., Shannon H., et al. Defining obesity cut points in a multiethnic population. Circulation 115 (2007) 2111-2118
6. Ford E. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 228 (2005) 1769-1778
7. Sullivan P., Ghushchyan V., Wyatt H., et al. Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity 15 (2007) 511-521
8. Ritchie S., and Connell J. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 17 (2007) 319-326
9. Ford E., Ajani U., Croft J., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 356 (2007) 2388-2398
10. Steinberg B., and Cannon C. Managing cardiometabolic risk-a brief review. In: Cefalu W., and Cannon C. (Eds). Atlas of Cardiometabolic Risk (2007), Informa Healthcare USA, Inc, New York, NY 137-165 Chapter 8
11. Hossain P., Kawar B., and El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 356 (2007) 213-215
12. National Institutes of Health: National Heart, Lung, and Blood Institute Obesity Education Initiative. The Practical Guide. Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.
13. (October 12, 2007). http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf Accessed
14. Parikh N., Pencina M., Wang T., et al. Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med 120 (2007) 242-250
15. Tangalos E., Cota D., and Fujioka K. Complex cardiometabolic risk factors: Impact, assessment, and emerging therapies. J Am Med Dir Assoc 7 Suppl (2006) 10-11
16. Ostbye T., Dement J., and Krause K. Obesity and workers compensation: Results from the Duke Health and Safety Surveillance System. Arch Intern Med 167 (2007) 766-773
17. Mello M., Studdert D., and Brennan T. Obesity-the new frontier of public health law. N Engl J Med 354 (2006) 2601-2610
18. Adams K., Schatzkin A., Harris T., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355 (2006) 77-778
19. Aronne L. Therapeutic options for modifying cardiometabolic risk factors. Am J Med 120 Suppl (2007) S26-S34
20. Rexrode K., Carey V., Hennekens C., et al. Abdominal adiposity and coronary heart disease in women. JAMA 280 (1998) 1843-1848
21. Gadde K., and Allison D. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 114 (2006) 974-984
22. Pi-Sunyer X., Blackburn G., Brancati F., et al., for the Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the Look AHEAD trial. Diabetes Care 30 (2007) 1374-1383
23. Bray G., and Ryan D. Drug treatment of the overweight patient. Gastroenterology 132 (2007) 2239-2252
24. Chobanian A., Bakris G., Black H., et al., for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 289 (2003) 2560-2572
25. MacMahon S. Antihypertensive drug treatment: The potential, expected and observed effects on vascular disease. J Hypertens 88 Suppl (1990) S239-S244
26. Lewington S., Clarke R., Qizilbash N., et al., for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
27. El-Atat F., McFarlane S., and Sowers J. Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. Curr Hypertens Rep. 6 (2004) 215-223
28. Neal B., MacMahon S., Chapman N., and for the Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists Collaboration. Lancet 33 (2000) 1955-1964
29. Bangalore S., Messerli F., Kostis J., and Pepine C. Cardiovascular protection using beta-blockers: A critical review of the evidence. J Am Coll Cardiol 50 (2007) 55-572
30. He J., and Whelton P. Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 138 (1999) 211-219
31. Scholze J., Grimm E., Herrmann D., et al. Optimal treatment of obesity-related hypertension: The Hypertension-Obesity-Sibutramine (HOS) study. Circulation 115 (2007) 1991-1998
32. LaRosa J., Grundy S., Waters D., et al., for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
33. Baigent C., Keech A., Kearney P., et al., for the Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
34. Cannon C., Braunwald E., McCabe C., et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
35. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl (2007) S4-S41
36. Chapman M. Beyond the statins: New therapeutic perspectives in cardiovascular disease prevention. Cardiovasc Drugs Ther. 19 (2005) 135-139
37. Kahn R. Metabolic syndrome: Is it a syndrome? Does it matter?. Circulation 115 (2007) 1806-1810
38. Caballero A. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes Res 11 (2003) 1278-1289
39. Lindström J., Ilanne-Parikka P., Peltonen M., et al., for the Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by life-style intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet 368 (2006) 1673-1679
40. Knowler W., Barrett-Connor E., Fowler S., et al., for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
41. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368 (2006) 1096-1105
42. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
43. Son S. Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes. Diabetes Res Clin Pract 77 Suppl (2007) S65-S70
44. Ahmed N., and Thornalley P. Advanced glycation endproducts: What is their relevance to diabetic complications?. Diabetes Obes Metab. 9 (2007) 233-245
45. Piconi L., Quagliaro L., Assaloni R., et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 22 (2006) 198-203
46. Franco O., Steyerberg E., Hu F., et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 167 (2007) 1145-1151
47. Fox C., Coady S., Sorlie P., et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation 115 (2007) 1544-1550
48. Kirkman M., Williams S., Caffrey H., and Marrero D. Impact of a program to improve adherence to diabetes guidelines by primary care physicians. Diabetes Care 25 (2002) 1946-1951
49. Lee M., and Aronne L. Weight management for type 2 diabetes mellitus: Global cardiovascular risk reduction. Am J Cardiol 99 (2007) 68B-79B
50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
51. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 33 (1998) 854-865
52. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 (2002) 2563-2569
53. Stettler C., Allemann S., Juni P., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 152 (2006) 27-38
54. Sidhu J., Kaposzta Z., Markus H., and Kaski J. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 (2004) 930-934
55. Mazzone T., Meyer P., Feinstein S., et al. Effect of pioglitazone compared with glimepiride on carotid intimamedia thickness in type 2 diabetes: A randomized trial. JAMA 296 (2006) 2572-2581
56. Meisner F., Walcher D., Gizard F., et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: Data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 26 (2006) 845-850
57. Home P., Pocock S., Beck-Nielsen H., et al., for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
58. Nissen S., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
59. Diamond G., Bax L., and Kaul S. Uncertain effects of rosiglitazone n he risk or yocardial nfarction and cardiovascular death. Ann Intern Med 147 (2007) 578-581
60. Dormandy J., Charbonnel B., Eckland D., et al., for the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study PROspective pioglitAzone clinical trial In macroVascular Events): A randomised controlled trial. Lancet 366 (2005) 1279-1289
61. Tenenbaum A., Motro M., and Fisman E. Dual and panpero oxis so om me proliferator-activated receptors (PPPAR) co-agonism: The bezafib brate le esso ons. Cardiovasc Diabetol 44 (2005) 14-18
62. Rodgers P., and Fuke D. New and emerging strategies for reducing cardiometabolic risk factors. Pharmacotherapy 26 (2006) 13S-31S
63. Nissen S., Wolski K., and Topol E. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
64. Nissen S. Adverse events related to muraglitazar use in diabetes-reply. JAMA 295 (2006) 1998
65. Hoogwerf B. Exenatide and pramlintide: New glucose-lowering agents for treating diabetes mellitus. Cleve Clin J Med 73 (2006) 477-484
66. Jones M. Therapies for diabetes:Pramlintide and exenatide. Am Fam Physician 75 (2007) 1831-1835
67. Drucker D., and Nauck M. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
68. Gallwitz B. Review of sitagliptin phosphate: A novel treatment for type 2 diabetes. Vasc Health Risk Manag. 3 (2007) 203-210
69. Schaefer E., and Asztalos B. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol 17 (2006) 394-398
70. Woods S. Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med. 120 Suppl 1 (2007) S19-S25
71. Duffy D., and Rader D. Endocannabinoid antagonism: Blocking the excess in the treatment of high-risk abdominal obesity. Trends Cardiovasc Med 17 (2007) 35-43
72. Van Gaal L., and Peiffer F. New approaches for the management of patients with multiple cardiometabolic risk factors. J Endocrinol Invest 29 Suppl (2006) 83-89
73. Kakafika A., Mikhailidis D., Karagiannis A., and Athyros V. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 47 (2007) 642-652